3T2 Stock Overview
An in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
T2 Biosystems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.48 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$0.37 |
| Beta | 0.38 |
| 11 Month Change | -52.91% |
| 3 Month Change | -84.30% |
| 1 Year Change | n/a |
| 33 Year Change | -99.98% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3T2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.6% | -0.2% | 0.8% |
| 1Y | n/a | -16.9% | 9.1% |
Return vs Industry: Insufficient data to determine how 3T2 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 3T2 performed against the German Market.
Price Volatility
| 3T2 volatility | |
|---|---|
| 3T2 Average Weekly Movement | 16.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3T2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3T2's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 113 | John Sperzel | www.t2biosystems.com |
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens.
T2 Biosystems, Inc. Fundamentals Summary
| 3T2 fundamental statistics | |
|---|---|
| Market cap | €10.01m |
| Earnings (TTM) | -€41.00m |
| Revenue (TTM) | €7.33m |
1.4x
P/S Ratio-0.2x
P/E RatioIs 3T2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3T2 income statement (TTM) | |
|---|---|
| Revenue | US$7.68m |
| Cost of Revenue | US$27.72m |
| Gross Profit | -US$20.05m |
| Other Expenses | US$22.91m |
| Earnings | -US$42.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.09 |
| Gross Margin | -261.12% |
| Net Profit Margin | -559.52% |
| Debt/Equity Ratio | -101.8% |
How did 3T2 perform over the long term?
See historical performance and comparison